Latest Pathology Services News

Healius has secured a national pathology services agreement with Ramsay Health Care subsidiaries, consolidating its role across 13 hospitals and stabilising a key revenue stream worth around $45 million annually.

Healius updates FY26 guidance with modest earnings growth, flags wage cost pressures from Fair Work ruling, and initiates sale process for high-growth Agilex Biolabs.

Healius Limited reported solid half-year results for 1H26, with revenue growth driven by pathology and Agilex Biolabs, alongside significant progress in digital transformation and AI integration.

Australian Clinical Labs reported a modest revenue dip but achieved growth in earnings and margins in 1H26, while updating FY26 guidance and addressing wage increases mandated by the Fair Work Commission.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Healius Limited has landed a significant five-year contract to provide pathology services to the Australian Defence Force, leveraging its national network and digital health solutions.

Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Australian Clinical Labs has reached a $6.2 million settlement with the Australian Information Commissioner to resolve a Federal Court case stemming from a 2022 cyberattack on its newly acquired Medlab Pathology business.

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

Australian Clinical Labs reported robust FY25 financial results with revenue and earnings growth, alongside a strong dividend payout and positive outlook for FY26.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.